Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity

Biochemical Pharmacology

Volumn 59, Issue 4, 2000, Pages 347-356

  Sudo, Toshiki ^a   Tachibana, Kazue ^a   Toga, Kazuyuki ^a   Tochizawa, Shirou ^a   Inoue, Yoshihiro ^a   Kimura, Yukio ^a   Hidaka, Hiroyoshi ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cilostamide; Cyclic AMP; OPC 33540; Phosphodiesterase 3 inhibitor; Platelet aggregation; Recombinant enzyme

Indexed keywords

6 [3 [3 CYCLOOCTYL 3 (2 HYDROXYCYCLOHEXYL)UREIDO]PROPOXY] 2(1H) QUINOLINONE; AMRINONE; ANTITHROMBOCYTIC AGENT; CILOSTAMIDE; CILOSTAMIDE DERIVATIVE; CILOSTAZOL; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ISOENZYME; MILRINONE; PROSTAGLANDIN E1; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BACULOVIRUS; CATTLE; CELL CULTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TRANSFER; IN VITRO STUDY; INSECT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION INHIBITION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BLOOD PLATELETS; CELLS, CULTURED; CYCLIC AMP; HUMANS; ISOENZYMES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; QUINOLINES; QUINOLONES; RECOMBINANT PROTEINS; SEMICARBAZIDES; UREA;

EID: 0033985281     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00346-9     Document Type: Article

References (41)

1. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 46:1994;399-405.
2. Fisher D.A., Smith J.F., Pillar J.S., St. Denis S.H., Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 246:1998;570-577.
3. Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S., Kawarada Y., Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun. 250:1998;751-756.
4. Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 273:1998;15553-15558.
5. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 274:1999;18438-18445.
6. Beavo J.A. Cyclic nucleotide phosphodiesterases Functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
7. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 36:1996;403-427.
8. Rose R.J., Liu H., Palmer D., Maurice D.H. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol. 122:1997;233-240.
9. Reeves M.L., Leigh B.K., England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J. 241:1987;535-541.
10. m phosphodiesterase. Biochim Biophys Acta. 429:1976;485-497.
11. Hidaka H., Hayashi H., Kohri H., Kimura Y., Hosokawa T., Igawa T., Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther. 211:1979;26-30.
12. Nicholson C.D., Challiss R.A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 12:1991;19-27.
13. Souness J.E., Hassall G.A., Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 44:1992;857-866.
14. Inoue Y., Toga K., Tachibana K., Kimura Y., Hidaka H. Prevention of intimal proliferation by cilostamide. Atherosclerosis. 109:1994;253.
15. Indolfi C., Avvedimento E.V., Lorenzo E.D., Esposito G., Rapacciuolo A., Giuliano P., Grieco D., Cavuto L., Stingone A.M., Ciullo I., Condorelli G., Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 3:1997;775-779.
16. Umekawa H., Tanaka T., Kimura Y., Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol. 33:1984;3339-3344.
17. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 35:1985;1144-1149.
18. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320.
19. Koga Y., Kihara Y., Okada M., Inoue Y., Tochizawa S., Toga K., Tachibana K., Kimura Y., Nishi T., Hidaka H. 2(1H)-Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Bioorg Med Chem Lett. 8:1998;1471-1476.
20. Bentley J.K., Kadlecek A., Sherbert C.H., Seger D., Sonnenburg W.K., Charbonneau H., Novack J.P., Beavo J.A. Molecular cloning of cDNA encoding a "63"-kDa calmodulin-stimulated phosphodiesterase from bovine brain. J Biol Chem. 267:1992;18676-18682.
21. Sonnenburg W.K., Mullaney P.J., Beavo J.A. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. J Biol Chem. 266:1991;17655-17661.
22. McAllister-Lucas L.M., Sonnenburg W.K., Kadlecek A., Seger D., Trong H.L., Colbran J.L., Thomas M.K., Walsh K.A., Francis S.H., Corbin J.D., Beavo J.A. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem. 268:1993;22863-22873.
23. Bloom T.J., Beavo J.A. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA. 93:1996;14188-14192.
24. Swinnen J.V., Joseph D.R., Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase Evidence for a family of genes . Proc Natl Acad Sci USA. 86:1989;5325-5329.
25. Endo T., Tanaka T., Isobe T., Kasai H., Okuyama T., Hidaka H. Calcium-dependent affinity chromatography of S-100 and calmodulin on calmodulin antagonist-coupled Sepharose. J Biol Chem. 256:1981;12485-12489.
26. Sudo T., Hidaka H. Regulation of calcyclin (S100A6) binding by alternative splicing in the N-terminal regulatory domain of annexin XI isoforms. J Biol Chem. 273:1998;6351-6357.
27. Meacci E., Taira M., Moos M., Smith C.J., Movsesian M.A., Degerman E., Belfrage P., Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 89:1992;3721-3725.
28. Taira M., Hockman S.C., Calvo J.C., Taira M., Belfrage P., Manganiello V.C. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem. 268:1993;18573-18579.
29. Leroy M.-J., Degerman E., Taira M., Murata T., Wang L.H., Movsesian M.A., Meacci E., Manganiello V.C. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry. 35:1996;10194-10202.
30. Leibowitz M.D., Biswas C., Brady E.J., Conti M., Cullinan C.A., Hayes N.S., Manganiello V.C., Saperstein R., Wang L., Zafian P.T., Berger J. A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes. 44:1995;67-74.
31. Dickinson N.T., Jang E.K., Haslam R.J. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets Effects on platelet aggregation . Biochem J. 323:1997;371-377.
32. Nagakura N., Saeki T., Harada K., Yoshitake S., Kobayashi S., Yamanaka T., Saito I. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 19:1996;828-833.
33. Tang K.M., Jang E.K., Haslam R.J. Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets. Biochem J. 323:1997;217-224.
34. Thompson W.J., Appleman M.M. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem. 246:1971;3145-3150.
35. Yan C., Zhao A.Z., Bentley J.K., Loughney K., Ferguson K., Beavo J.A. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci USA. 92:1995;9677-9681.
36. 2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem J. 310:1995;975-982.
37. Miyahara M., Ito M., Ito H., Shiraishi T., Isaka N., Konishi T., Nakano T. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta Characterization and the effects of E4021 . Eur J Pharmacol. 284:1995;25-33.
38. Stroop S.D., Beavo J.A. Sequence homology and structure-function studies of the bovine cyclic-GMP-stimulated and retinal phosphodiesterases. Adv Second Messenger Phosphoprotein Res. 25:1992;55-71.
39. Degerman E., Belfrage P., Newman A.H., Rice K.C., Manganiello V.C. Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem. 262:1987;5797-5807.
40. Ashida S., Sakuma K. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. Adv Second Messenger Phosphoprotein Res. 25:1992;229-239.
41. Degerman E., Belfrage P., Manganiello V.C. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 272:1997;6823-6826.